Select region:

Clinical trials located in

Bradford

Bradford city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Bradford, located in West Yorkshire, England, is renowned for its rich industrial heritage and vibrant cultural scene. Once the wool capital of the world, the city played a pivotal role during the Industrial Revolution. Bradford is also celebrated for its UNESCO City of Film status, a testament to its contributions to the film industry. The city boasts impressive Victorian architecture, including the grand City Hall. Bradford is home to the National Science and Media Museum, reflecting its ongoing commitment to the arts and sciences.

  • CT-EU-00057072

    Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    BelgiumDenmarkFranceGermanyNetherlandsSpainSwedenUnited Kingdom
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsSpainUnited Kingdom
  • Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    BelgiumFranceItalyPolandSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Researching vamikibart for uveitic macular edema treatments

    The study investigates Vamikibart, a new drug for adults with uveitic macular edema, a condition causing swelling in the eye and vision problems. It tests how well Vamikibart, given as eye injections, can improve vision compared to a sham procedure. The goal is to find a safe, effective treatment for this eye condition, helping people see better and manage their symptoms.

    AustriaItalyNetherlandsPolandPortugalUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Benralizumab’s impact on severe asthma study

    The study will examine the effects of a drug called benralizumab on people suffering from a severe type of asthma called eosinophilic asthma. Scientists will do this by using special imaging technology called functional airway imaging (FRI) to take pictures of the lungs before and after treatment. It’s an open-label trial, which means everyone knows that the asthma drug under investigation is benralizumab. The study will last from 15 to 23 weeks. Participants in this study must be adults (18 years of age or older), both men and women, who already have severe eosinophilic asthma. Their asthma is not currently well treated with regular inhalers or other asthma medications. One of the goals of the study is to see if benralizumab helps reduce airway resistance and clear mucus in the lungs. Scientists will measure parameters such as lung volume, airway resistance and mucus accumulation.

    BelgiumFrancePortugalSpainUnited Kingdom
  • Exploring new asthma treatment for adults

    This clinical trial evaluates londamocitinib (AZD4604), a potential new treatment for adults with moderate-to-severe asthma uncontrolled by standard inhalers (ICS-LABA). Participants will receive AZD4604 or a placebo via a dry-powder inhaler over 12 weeks. The trial aims to assess the drug’s effectiveness in managing asthma symptoms and its safety. It focuses on adults whose asthma is not well-controlled by current medications, seeking to offer a new therapeutic option.

    BulgariaDenmarkFranceGermanySpainSwedenUnited Kingdom
  • Studying tozorakimab for long-term safety in patients with chronic obstructive pulmonary disease

    The research study focuses on Tozorakimab’s long-term safety and efficacy in adults over 40 with frequent COPD flare-ups. It aims to evaluate the time until the first severe flare-up post-treatment, comparing it with the effects of current COPD treatments. The study also assesses Tozorakimab’s additional benefits alongside standard care and monitors participants’ blood for drug levels and physiological reactions. This research is key in developing improved management strategies for COPD.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Benralizumab trial for Chronic Lung Disease (COPD) patients

    This Phase 3 clinical trial evaluates Benralizumab in treating COPD, a severe lung condition characterized by breathing difficulties. It specifically targets individuals who experience frequent flare-ups, despite ongoing medication. The trial requires participants to have had at least two flare-ups in the previous year and a high eosinophil count in their blood. The study involves administering Benralizumab for a minimum of 56 weeks, with the aim to assess its impact on reducing flare-ups and improving lung function.

    AustriaBelgiumBulgariaDenmarkGermanyGreeceHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Advancing asthma management: study evaluates triple therapy inhaler

    This Phase 3 study evaluates the PT010 inhaler, a combination of budesonide, glycopyrronium, and formoterol, in adults and adolescents with inadequately controlled asthma. The study compares PT010 to standard treatments, assessing its effectiveness in improving lung function and reducing asthma exacerbations. Approximately, 2200 participants will be enrolled and monitored over 24 to 52 weeks. The trial aims to improve asthma management and quality of life for those with persistent symptoms despite current treatments.

    CzechiaGermanyGreecePortugalSlovakiaUnited Kingdom
  • Assessing the efficacy of atuliflapon in uncontrolled asthma relief

    This study is looking at atuliflapon, a new medication, for adults with moderate to severe uncontrolled asthma. The trial is a Phase 2 study, which means it’s testing how effective and safe atuliflapon is. About 1,102 adults who are already using asthma medications will be part of this study. They will take atuliflapon or a placebo once a day for 12 weeks. The goal is to see if atuliflapon can help reduce asthma attacks and improve breathing in people whose asthma isn’t well-controlled with their current treatments.

    BulgariaGermanyHungaryItalyNetherlandsPolandRomaniaSlovakiaSloveniaSpainUnited Kingdom
  • Research study on COPD treatment with new drug mitiperstat

    This study is testing a new drug, mitiperstat, for people with moderate to severe chronic obstructive pulmonary disease (COPD). It’s a Phase IIa trial where 288 adults will either get mitiperstat or a placebo. This setup allows researchers to compare the effects of mitiperstat against no treatment to determine if it effectively reduces the severity and frequency of COPD symptoms. The aim is to see if mitiperstat can help reduce COPD symptoms and how safe it is. Participants will take the drug or placebo once a day.

    BulgariaDenmarkGermanyItalyNetherlandsPolandSpainUnited Kingdom
  • Tozorakimab trial for chronic obstructive pulmonary disease (COPD) treatment

    This study is checking the effectiveness and safety of two different dose levels of a medication called tozorakimab for treating adults suffering from a long-term lung disease known as symptomatic chronic obstructive pulmonary disease (COPD). COPD patients participating in this study must have had at least two ‘moderate’ or one ‘severe’ exacerbations (flare-ups) over the last year. The study will compare how well tozorakimab works compared to an inactive substance (placebo) in delaying the time to the first exacerbation and any changes to lung function tests, such as the FEV1 test. The participants’ demonstrations of improvement based on scoring systems related to symptoms severity will also be evaluated.

    FranceGermanyGreeceItalyPolandRomaniaUnited Kingdom
  • Exploring the efficacy and safety of new drug in Psoriasis Treatment

    This clinical trial is for patients suffering from a skin condition called mild to moderate psoriasis. The aim of the study is to check the effectiveness and safety of a new drug called HRO350. HRO350 is a soft capsule containing oil extracted from herring roe (fish roe). This oil contains natural substances called phospholipids, which are rich in certain fatty acids. These substances have the potential to slow or stop the inflammation that causes psoriasis. Patients in the study will take HRO350 capsules or a placebo (a dummy medicine that contains no active substance) every day for up to a year. They will also have an 8-week follow-up period after completing treatment. Approximately 519 patients will participate in the study. The test will involve regular check-ups, including blood and urine tests, and an assessment of the severity of patients’ psoriasis.

    FinlandGermanyNorwayPolandUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom

See more clinical trials in other cities in United Kingdom:

.